DNTH | Ticker Profile - Titan Protect

DNTH

Dianthus Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$80.51

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-18.63

Based on estimated future earnings — lower means cheaper

Rev Growth

-60.2%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-22.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$122.50

+52% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 12 analysts covering this stock

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

https://dianthustx.com

Country: United States Employees: 92 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.381

Excellent risk-adjusted returns

Kelly Fraction

0.1011

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.055

Returns exceed worst-case losses — strong risk profile

Annual Return

103.4%

Historical annualised return based on price data

Max Drawdown

-50.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.09

Very low correlation to market moves

52W High

$96.50

17% below the year high

52W Low

$16.64

384% above the year low

Avg Volume

931,786

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.5%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.23

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.11

Conservative use of debt — low financial risk

Current Ratio

29.25

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

29.06

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-10,050.3%

Profit from core operations before interest and tax

Free Cash Flow

$-71,029,624

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-173,660,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$200.00

Target Median

$122.50

Target Low

$98.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go